Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 16/20 | 0.62 |
| ▸ | CYP11B2 | P19099 | 13/20 | 0.62 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2675048 | 0.86 | CYP11B1 (0.58) | CYP11B1CYP11B2RORCNR1H3 | |
| SCHEMBL1396483 | 0.85 | CYP11B1 (0.49) | CYP11B1CYP11B2RORCNR1H3AR | |
| SCHEMBL1396370 | 0.84 | CYP11B1 (0.53) | CYP11B1CYP11B2RORCNR1H3HSD11B1 | |
| SCHEMBL16520294 | 0.82 | CYP11B1 (0.55) | CYP11B1CYP11B2RORCNR1H3HSD11B1 | |
| SCHEMBL1396364 | 0.81 | CYP11B1 (0.49) | CYP11B1CYP11B2RORCNR1H3 | |
| SCHEMBL1396322 | 0.81 | CYP11B1 (0.49) | CYP11B1CYP11B2RORCNR1H3 | |
| SCHEMBL13573348 | 0.78 | CYP11B1 (0.42) | CYP11B1CYP11B2AR | |
| SCHEMBL1396489 | 0.76 | CYP11B1 (0.53) | CYP11B1CYP11B2 | |
| SCHEMBL12455462 | 0.76 | CYP11B1 (0.48) | CYP11B1CYP11B2 | |
| SCHEMBL1396337 | 0.75 | CYP11B1 (0.53) | CYP11B1CYP11B2RORCNR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2288605-B1 | ANNELATED PYRROLIDIN SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2014-06-25 | — | — | EP | disclosed |
| EP-2288605-B1 | ANNELATED PYRROLIDIN SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2014-06-25 | — | — | EP | disclosed |
| US-8329725-B2 | Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals | SANOFI (FR) | 2012-12-11 | — | — | US | disclosed |
| US-8329725-B2 | Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals | SANOFI (FR) | 2012-12-11 | — | — | US | disclosed |
| US-8329725-B2 | Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals | SANOFI (FR) | 2012-12-11 | — | — | US | disclosed |
| US-20110207738-A1 | ANNELATED PYRROLIDIN SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2011-08-25 | — | — | US | disclosed |
| US-20110207738-A1 | ANNELATED PYRROLIDIN SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2011-08-25 | — | — | US | disclosed |
| US-20110207738-A1 | ANNELATED PYRROLIDIN SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2011-08-25 | — | — | US | disclosed |
| EP-2288605-A1 | ANNELATED PYRROLIDIN SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2011-03-02 | — | — | EP | disclosed |
| WO-2009149819-A1 | ANNELATED PYRROLIDIN SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207738-A1 | ANNELATED PYRROLIDIN SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | PPARD, PPARA, PPARG | CYP11B1 294/4885CYP11B2 319/4885RORC 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.